doi: 10.1016/j.stemcr.2014.09.002 [PMC free article] [PubMed] [CrossRef] [Google Scholar] 60. pluripotent stem cellCderived cardiomyocytes to symbolize clinical findings in the nonclinical research space, and future directions for their further use. strong class=”kwd-title” Keywords: AHA Edoxaban Scientific Statements, biomarkers, cardiotoxicity, electrophysiology, human stem cell-derived cardiomyocytes, myocardial contraction, wounds and injuries In the United States and Europe, cancer is the second leading cause of death and morbidity after cardiovascular disease (CVD).1 On a global scale, malignancy accounted for 9.6 million deaths in 2018.2 Fortunately, present-day malignancy treatment strategies have resulted in dramatic improvement in the survival of patients diagnosed with malignancy. In 2016, there were an estimated 15.5 million cancer survivors in the United States, and this number is expected to increase to 20.3 million by 2026.3 However, such gains in both quantity and quality of life are at risk of Edoxaban being partially erased by the increased mortality and morbidity from therapy-related CVD side effects.4 The incidence of all cancers increases with age, which increases the quantity of cancer survivors who may have concomitant risk factors for cardiac disease at the time of diagnosis.5 The use of cytotoxic chemotherapy is rising as Edoxaban cancer survival is improving.6 Together, these factors mean that malignancy is becoming a chronic illness, which creates an ever-pressing need to address both short- and long-term cardiotoxic effects of malignancy therapy. Cardiovascular complications of malignancy therapy significantly contribute to the global burden of CVD, and the success in treating malignancy has produced a large cohort of malignancy survivors with increased risk of chronic multisystemic diseases.7 Life-threatening complications of congestive heart failure, thrombogenesis, pericardial disease, hypertension, myocardial ischemia, cardiac arrhythmias, and vasospasm8,9 have all been linked to cancer therapies such as cytotoxic chemotherapies, molecularly targeted therapies, and mediastinal irradiation, resulting in cardiomyocyte and vascular damage.10 Malignancy survivors may have markedly reduced life expectancy with evidence of coronary artery disease in their 30s, especially if additional risk factors such as hypertension, diabetes mellitus, obesity, and dyslipidemia are also present.11,12 In particular, congestive heart failure as a result of malignancy therapy has been linked to a 3.5-fold increased mortality risk compared with idiopathic cardiomyopathy.13 The long-term risk of death resulting from CVD may exceed the risk of recurrence for many forms of cancer.14,15 Therefore, as the population of cancer survivors grows, it is essential to recognize the need for early assessment of potential risks of acute and chronic cardiotoxicity. To that end, a better understanding of the mechanisms of malignancy therapyCrelated cardiac toxicity is usually important to develop effective preventive approaches such as novel preclinical screening tools and methods that can assess the security and efficacy of currently available and future therapies. The focus of this scientific statement is the power and potential promise of human induced pluripotent stem cell (hiPSC)Cderived cardiomyocytes (hiPSC-CMs) in preclinical screening of drug-induced cardiotoxicity. Although there is usually overlap, it is useful to consider cardiotoxicity in 3 groups: electrophysiological abnormalities, contractile dysfunction, and structural toxicity. Although touching on all 3 groups, this review emphasizes toxicity related to myocardial injury with the use of in vitro hiPSC-CM preparations. Contractile dysfunction, usually the first clinical manifestation of drug-induced cardiotoxicity, is usually EBR2 often associated with structural cardiotoxicity. The detection of structural cardiotoxicity with hiPSC-CMs in vitro may guideline the evaluation of cardiac liabilities, the synthesis of safer molecules, and the design of more useful early clinical studies. The basic aspects of electrophysiological (proarrhythmia) toxicity and the ability of hiPSC-CMs to detect such effects, specifically those.